Database

Netherlands Translation Research Center B.V. (NTRC)

Solution provided
Technology
Supplier identity
General description

Netherlands Translational Research Center B.V. (NTRC) develops small molecule drug leads and preclinical candidates for cancer, autoimmune disease and Parkinson’s disease. NTRC bridges the innovation gap between pharmaceutical industries and universities by connecting its drug discovery expertise’s (i.e., assay development, screening, x-ray crystallography and medicinal chemistry) with disease biology know-how at academic centers. NTRC has several products (listed below).

Type of Supplier
Research Institution
Sector of activity
  • Cancer / Oncology
  • Drug Discovery / Research & Development
  • Immunology
Region
Province of Noord Brabant, NL
Regional access broker
  • Ria Hein, Noord-Brabant Development Agency (BOM)
Activity description
The 3 top equipments available

Our state of facility has access to:

  • Biacore T100 for measuring binding kinetics of small molecules on proteins
  • Advanced equipment for biochemical and cellular assays (e.g. Perkin-Elmer Envision Reader)
  • Access to HTS core  facilities of Pivot Park in Oss
  • http://www.ntrc.nl/technlogies/oncolinestm: At NTRC we have set up Oncolines™, a unique panel of cancer cell lines derived from a diverse set of human tumors. Oncolines™ represents quantitatively 95 % of all mutations in cancer genes that have been identified in larger panels and also reflect the tissue distribution of larger panels.
     
Know-how, expertise available

Assay development

Cell based assays (Oncolines™ cancer cell line panel, G protein-coupled receptors)

Biochemical assays

Protein production

Protein crystallography

Medicinal chemistry

Possibilities of partnership

Fee-for-service

Joint drug discovery

Consultancy

Services provided

OncolinesTM

Oncolines™ is a unique panel of cancer cell lines derived from a diverse set of human tumors. The Oncolines™ cancer cell line panel represents quantitatively 95 % of all mutations in cancer genes that drive tumors progression. Compounds are tested on the panel with a short turn-around time and bioinformatics analysis of the data is included. Cell lines from the Oncolines™ panel can be cherry-picked for customer-defined subpanel testing.

 

SynergyFinder™

With SynergyFinder™ favorable interactions between a customer lead compound and existing chemotherapeutic agents can be determined in the cell lines of choice from the Oncolines™ panel.

SynergyFinder™ helps to ensure that new therapies are combined in the best way possible with established therapies, or other new therapies.

 

Target Residence Time

Target residence time has become a vital optimization parameter for driving pharmacodynamic efficacy and drug selectivity. Target residence time of small molecule compounds is determined using Biacore T100.

 

Partnership Carna

NTRC has a strategic alliance with Carna Biosciences Inc. in Japan. Through this partnership NTRC offers selectivity profiling of compounds in biochemical kinase enzyme activity assays.

Training and Staff possibilities
No
Contact information
Name
Zaman
Surname
Guido
Function
Head of Biology
Phone number
0412-700500
Email address
info@ntrc.nl
Website Address
http://www.ntrc.nl
Address
Molenstraat 110
5342 CC  Oss
Netherlands